Mouse IL-1β enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.91 pg/ml (10 μl) |
| Standard Curve Range | 15.63~1000 pg/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0651 | 0.0701 | 0.0676 | |
| 15.63 | 0.1104 | 0.1143 | 0.1124 | 0.0448 |
| 31.25 | 0.1660 | 0.1609 | 0.1635 | 0.0959 |
| 62.50 | 0.2623 | 0.2676 | 0.2650 | 0.1974 |
| 125.00 | 0.4740 | 0.4650 | 0.4695 | 0.4019 |
| 250.00 | 0.8593 | 0.8316 | 0.8455 | 0.7779 |
| 500.00 | 1.5070 | 1.6060 | 1.5565 | 1.4889 |
| 1000.00 | 2.7780 | 2.8080 | 2.7930 | 2.7254 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 18.9 | 93.0 | 290.2 | 17.4 | 97.5 | 280.7 |
| Standard Deviation | 1.0 | 4.5 | 16.9 | 2.3 | 8.5 | 14.6 |
| Coefficient of Variation(%) | 5.3 | 4.9 | 5.8 | 6.1 | 6.1 | 5.7 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested Twenty-two times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of mouse IL-1 beta into health mouse serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 81% to 111% with an overall mean recovery of 98%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | n.d.-3.66 | 13 | 1.08 |
Serum/Plasma – Thirty samples from apparently healthy mice were evaluated for the presence of IL-1β in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: IL-1β
The Interleukin 1 (IL-1) family of proteins consists of IL-1 alpha, IL-1 beta, and the IL-1 receptor antagonist (IL-1ra). IL-1 alpha and IL-1 beta bind to the same cell surface receptors and share biological functions. IL-1 is not produced by unstimulated cells of healthy individuals with the exception of skin keratinocytes, some epithelial cells, and certain cells of the central nervous system. However, in response to inflammatory agents, infections, or microbial endotoxins, a dramatic increase in the production of IL-1 by macrophages and various other cell types is seen. IL-1 beta plays a central role in immune and inflammatory responses, bone remodeling, fever, carbohydrate metabolism, and GH/IGF-I physiology. Inappropriate or prolonged production of IL-1 has been implicated in a variety of pathological conditions including sepsis, rheumatoid arthritis, inflammatory bowel disease, acute and chronic myelogenous leukemia, insulindependent diabetes mellitus, atherosclerosis, neuronal injury, and aging-related diseases.
IL-1 alpha and IL-1 beta are structurally related polypeptides that show approximately 25% homology at the amino acid (aa) level. Both are synthesized as 31 kDa precursors that are subsequently cleaved into mature proteins of approximately 17.5 kDa. Cleavage of the IL-1 beta precursor by Caspase-1/ICE is a key step in the inflammatory response. Neither IL-1 alpha nor IL-1 beta contains a typical hydrophobic signal peptide, but evidence suggests that these factors can be secreted by non-classical pathways. A portion of unprocessed IL-1 alpha can be presented on the cell membrane and may retain biological activity. The precursor form of IL-1 beta, unlike the IL-1 alpha precursor, shows little or no biological activity in comparison to the processed form. Both unprocessed and mature forms of IL-1 beta are exported from the cell.
IL-1 alpha and IL-1 beta exert their effects through immunoglobulin superfamily receptors that additionally bind IL-1ra. The 80 kDa transmembrane type I receptor (IL-1 RI) is expressed on T cells, fibroblasts, keratinocytes, endothelial cells, synovial lining cells, chondrocytes, and hepatocytes. The 68 kDa transmembrane type II receptor (IL-1 RII) is expressed on B cells, neutrophils, and bone marrow cells. The two IL-1 receptor types show approximately 28% homology in their extracellular domains but differ significantly in that the type II receptor has a cytoplasmic domain of only 29 aa, whereas the type I receptor has a 213 aa cytoplasmic domain. IL-1 RII does not appear to signal in response to IL-1 and may function as a decoy receptor that attenuates IL-1 function. The IL-1 receptor accessory protein (IL-1 RAcP) associates with IL-1 RI and is required for IL-1 RI signal transduction. IL-1ra is a secreted molecule that functions as a competitive inhibitor of IL-1. Soluble forms of both IL-1 RI and IL-1 RII have been detected in human plasma, synovial fluids, and the conditioned media of several human cell lines. In addition, IL-1 binding proteins that resemble soluble IL-1 RII are encoded by vaccinia and cowpox viruses.
Under construction!
Under construction!
Under construction!
Citations
-
Harmine derivative ZLWH-38 ameliorates the therapeutic efficacy of colistin against XDR-Ab pneumonia by suppressing inflammatory responses
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Sept
-
Lipocalin 2 deficiency attenuates NLRP3 inflammasome activation through glycolysis impairment and MGST1-mediated mitochondrial ROS reduction
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Nov
-
Deciphering the Role of N-Acetyltransferase 10 in Thalamic Hemorrhage Through Integrative Multi-Omics and Experimental Validation
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Nov
-
PDCD4 inhibition alleviates neuropathic pain by regulating spinal autophagy and neuroinflammation
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Mar
-
A high-throughput reporter assay for screening potential gasdermin D inhibitors from natural products
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jan
-
Engineered Sporopollenin Exine Capsules for Colon-Targeted Delivery and Antioxidant Therapy of Pogostemon Oil in Ulcerative Colitis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jan
-
Inhibiting the NLRP3 inflammasome with MCC950 ameliorates muscle atrophy in cancer cachexia
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Feb
-
A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Feb
-
Inhibition of the α7 nicotinic acetylcholine receptor alleviates pyroptosis in blood-brain barrier induced by Cryptococcus neoformans
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Feb
-
Engineered M2 macrophage-derived vesicles deliver DNase I for cfDNA clearance and multi-organ protection in sepsis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Mar
-
Neuromodulation and Copper Chelation Reverse Sleep Fragmentation–Aggravated Myocardial Ischemia-Reperfusion Injury by Targeting NETs-Induced Endothelial Cuproptosis
Applications: ELISA
Reactivity:
Publish Date: 2026 Apr
-
DS-10 mitigates cerebral ischemia-reperfusion injury in mice through suppressing caspase-1-mediated pyroptosis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Apr
-
Sleep deprivation induces anxiety-like behaviors through IL-6 driven astrocyte-GABAergic neuron crosstalk in the PAG-ACC circuit
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 May
-
Serum amyloid A1 activates the NLRP3 inflammasome via TLR2 to mediate trichloroethylene-induced immune kidney injury
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 May
-
Fusobacterium nucleatum-derived succinic acid aggravates colitis by triggering macrophage pro-inflammatory phenotypic transformation via SUCNR1/NF-κB axis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jul
-
Targeted Delivery of Schisandrin A to Cardiac Endothelium Alleviates Myocardial Ischemia-Reperfusion Injury via Suppression of Ferroptosis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jul
-
Comparative Analysis of LPS/IFN-γ and LPS/ATP-Induced Inflammatory Models in BV2 Microglia
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Aug
-
Brain Penetration Optimization and Anti-neuroinflammation Evaluation of Potent 6-Methyl-7-azaindol-3-yl-quinazoline DYRK1A Inhibitors for Alzheimer’s Disease
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Brassica rapa L. (Turnip) Ethanol Extract Alleviates Hyperuricemia by Modulating Purine Metabolism Enzymes and Renal Urate Transporters
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Bifidobacterium longum Subspecies infantis M63 Enhances the Colitis-Alleviating Effect of 2′-Fucosyllactose by Restoring Intestinal Barrier Function and Microbial Metabolism
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Hemolytic mechanism and virulence of Antarctic psychrophilic Pseudomonas
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
